Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles

被引:6
作者
Pons-Escoda, Albert [1 ,2 ,3 ,4 ]
Garcia-Ruiz, Alonso [5 ]
Naval-Baudin, Pablo [1 ,4 ]
Martinez-Zalacain, Ignacio [1 ,4 ]
Castell, Josep [1 ]
Camins, Angels [1 ]
Vidal, Noemi [2 ,6 ]
Bruna, Jordi [2 ]
Cos, Monica [1 ]
Perez-Lopez, Raquel [5 ]
Oleaga, Laura [7 ]
Warnert, Esther [8 ,9 ]
Smits, Marion [8 ,9 ,10 ]
Majos, Carles [1 ,2 ,4 ]
机构
[1] Hosp Univ Bellvitge, Radiol Dept, Feixa Llarga SN, Barcelona 08907, Spain
[2] Inst Invest Biomed Bellvitge IDIBELL, Neurooncol Unit, Feixa Llarga SN, Barcelona 08907, Spain
[3] Univ Barcelona UB, Fac Med & Ciencies Salut, Carrer Casanova 143, Barcelona 08036, Spain
[4] Bellvitge Biomed Res Inst IDIBELL, Diag Imaging & Nucl Med Res Grp, Feixa Llarga SN, Barcelona 08907, Spain
[5] Vall dHebron Inst Oncol VHIO, Radiom Grp, Carrer Natzaret 115-117, Barcelona 08035, Spain
[6] Hosp Univ Bellvitge, Pathol Dept, Feixa Llarga SN, Barcelona 08907, Spain
[7] Hosp Clin Barcelona, Radiol Dept, Villarroel 170, Barcelona 08036, Spain
[8] Erasmus MC, Dept Radiol & Nucl Med, Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
[9] Erasmus MC, Canc Inst, Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
[10] Med Delta, Delft, Netherlands
关键词
Brain neoplasms; Astrocytoma; Oligodendroglioma; Perfusion imaging; Magnetic resonance imaging; DYNAMIC SUSCEPTIBILITY-CONTRAST; NERVOUS-SYSTEM LYMPHOMA; CONSENSUS RECOMMENDATIONS; GLIOBLASTOMA; DIFFUSE; MRI; IDENTIFICATION; PROTOCOL; CURVE;
D O I
10.1007/s00330-024-10611-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
ObjectivePresurgical differentiation between astrocytomas and oligodendrogliomas remains an unresolved challenge in neuro-oncology. This research aims to provide a comprehensive understanding of each tumor's DSC-PWI signatures, evaluate the discriminative capacity of cerebral blood volume (CBV) and percentage of signal recovery (PSR) percentile values, and explore the synergy of CBV and PSR combination for pre-surgical differentiation.MethodsPatients diagnosed with grade 2 and 3 IDH-mutant astrocytomas and IDH-mutant 1p19q-codeleted oligodendrogliomas were retrospectively retrieved (2010-2022). 3D segmentations of each tumor were conducted, and voxel-level CBV and PSR were extracted to compute mean, minimum, maximum, and percentile values. Statistical comparisons were performed using the Mann-Whitney U test and the area under the receiver operating characteristic curve (AUC-ROC). Lastly, the five most discriminative variables were combined for classification with internal cross-validation.ResultsThe study enrolled 52 patients (mean age 45-year-old, 28 men): 28 astrocytomas and 24 oligodendrogliomas. Oligodendrogliomas exhibited higher CBV and lower PSR than astrocytomas across all metrics (e.g., mean CBV = 2.05 and 1.55, PSR = 0.68 and 0.81 respectively). The highest AUC-ROCs and the smallest p values originated from CBV and PSR percentiles (e.g., PSRp70 AUC-ROC = 0.84 and p value = 0.0005, CBVp75 AUC-ROC = 0.8 and p value = 0.0006). The mean, minimum, and maximum values yielded lower results. Combining the best five variables (PSRp65, CBVp70, PSRp60, CBVp75, and PSRp40) achieved a mean AUC-ROC of 0.87 for differentiation.ConclusionsOligodendrogliomas exhibit higher CBV and lower PSR than astrocytomas, traits that are emphasized when considering percentiles rather than mean or extreme values. The combination of CBV and PSR percentiles results in promising classification outcomes.Clinical relevance statementThe combination of histogram-derived percentile values of cerebral blood volume and percentage of signal recovery from DSC-PWI enhances the presurgical differentiation between astrocytomas and oligodendrogliomas, suggesting that incorporating these metrics into clinical practice could be beneficial.Key Points center dot The unsupervised selection of percentile values for cerebral blood volume and percentage of signal recovery enhances presurgical differentiation of astrocytomas and oligodendrogliomas.center dot Oligodendrogliomas exhibit higher cerebral blood volume and lower percentage of signal recovery than astrocytomas.center dot Cerebral blood volume and percentage of signal recovery combined provide a broader perspective on tumor vasculature and yield promising results for this preoperative classification.Key Points center dot The unsupervised selection of percentile values for cerebral blood volume and percentage of signal recovery enhances presurgical differentiation of astrocytomas and oligodendrogliomas.center dot Oligodendrogliomas exhibit higher cerebral blood volume and lower percentage of signal recovery than astrocytomas.center dot Cerebral blood volume and percentage of signal recovery combined provide a broader perspective on tumor vasculature and yield promising results for this preoperative classification.Key Points center dot The unsupervised selection of percentile values for cerebral blood volume and percentage of signal recovery enhances presurgical differentiation of astrocytomas and oligodendrogliomas.center dot Oligodendrogliomas exhibit higher cerebral blood volume and lower percentage of signal recovery than astrocytomas. center dot Cerebral blood volume and percentage of signal recovery combined provide a broader perspective on tumor vasculature and yield promising results for this preoperative classification.
引用
收藏
页码:5320 / 5330
页数:11
相关论文
共 55 条
  • [1] An experimental comparison of cross-validation techniques for estimating the area under the ROC curve
    Airola, Antti
    Pahikkala, Tapio
    Waegeman, Willem
    De Baets, Bernard
    Salakoski, Tapio
    [J]. COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2011, 55 (04) : 1828 - 1844
  • [2] [Anonymous], 2021, World Health Organization Classification of Tumours of the Central Nervous System
  • [3] Prognostic relevance of genetic alterations in diffuse lower-grade gliomas
    Aoki, Kosuke
    Nakamura, Hideo
    Suzuki, Hiromichi
    Matsuo, Keitaro
    Kataoka, Keisuke
    Shimamura, Teppei
    Motomura, Kazuya
    Ohka, Fumiharu
    Shiina, Satoshi
    Yamamoto, Takashi
    Nagata, Yasunobu
    Yoshizato, Tetsuichi
    Mizoguchi, Masahiro
    Abe, Tatsuya
    Momii, Yasutomo
    Muragaki, Yoshihiro
    Watanabe, Reiko
    Ito, Ichiro
    Sanada, Masashi
    Yajima, Hironori
    Morita, Naoya
    Takeuchi, Ichiro
    Miyano, Satoru
    Wakabayashi, Toshihiko
    Ogawa, Seishi
    Natsume, Atsushi
    [J]. NEURO-ONCOLOGY, 2018, 20 (01) : 66 - 77
  • [4] High- and low-grade glioma differentiation: the role of percentage signal recovery evaluation in MR dynamic susceptibility contrast imaging
    Aprile, Italo
    Giovannelli, Giorgia
    Fiaschini, Paola
    Muti, Marco
    Kouleridou, Anna
    Caputo, Nevia
    [J]. RADIOLOGIA MEDICA, 2015, 120 (10): : 967 - 974
  • [5] Microvasculature Features Derived from Hybrid EPI MRI in Non-Enhancing Adult-Type Diffuse Glioma Subtypes
    Arzanforoosh, Fatemeh
    van der Voort, Sebastian R. R.
    Incekara, Fatih
    Vincent, Arnaud
    Van den Bent, Martin
    Kros, Johan M. M.
    Smits, Marion
    Warnert, Esther A. H.
    [J]. CANCERS, 2023, 15 (07)
  • [6] Preoperative Diagnosis and Molecular Characterization of Gliomas With Liquid Biopsy and Radiogenomics
    Balana, Carmen
    Castaner, Sara
    Carrato, Cristina
    Moran, Teresa
    Lopez-Paradis, Assumpcio
    Domenech, Marta
    Hernandez, Ainhoa
    Puig, Josep
    [J]. FRONTIERS IN NEUROLOGY, 2022, 13
  • [7] Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)
    Barajas, Ramon F., Jr.
    Politi, Letterio S.
    Anzalone, Nicoletta
    Schoder, Heiko
    Fox, Christopher P.
    Boxerman, Jerrold L.
    Kaufmann, Timothy J.
    Quarles, C. Chad
    Ellingson, Benjamin M.
    Auer, Dorothee
    Andronesi, Ovidiu C.
    Ferreri, Andres J. M.
    Mrugala, Maciej M.
    Grommes, Christian
    Neuwelt, Edward A.
    Ambady, Prakash
    Rubenstein, James L.
    Illerhaus, Gerald
    Nagane, Motoo
    Batchelor, Tracy T.
    Hu, Leland S.
    [J]. NEURO-ONCOLOGY, 2021, 23 (07) : 1056 - 1071
  • [8] Redefine statistical significance
    Benjamin, Daniel J.
    Berger, James O.
    Johannesson, Magnus
    Nosek, Brian A.
    Wagenmakers, E. -J.
    Berk, Richard
    Bollen, Kenneth A.
    Brembs, Bjoern
    Brown, Lawrence
    Camerer, Colin
    Cesarini, David
    Chambers, Christopher D.
    Clyde, Merlise
    Cook, Thomas D.
    De Boeck, Paul
    Dienes, Zoltan
    Dreber, Anna
    Easwaran, Kenny
    Efferson, Charles
    Fehr, Ernst
    Fidler, Fiona
    Field, Andy P.
    Forster, Malcolm
    George, Edward I.
    Gonzalez, Richard
    Goodman, Steven
    Green, Edwin
    Green, Donald P.
    Greenwald, Anthony
    Hadfield, Jarrod D.
    Hedges, Larry V.
    Held, Leonhard
    Ho, Teck Hua
    Hoijtink, Herbert
    Hruschka, Daniel J.
    Imai, Kosuke
    Imbens, Guido
    Ioannidis, John P. A.
    Jeon, Minjeong
    Jones, James Holland
    Kirchler, Michael
    Laibson, David
    List, John
    Little, Roderick
    Lupia, Arthur
    Machery, Edouard
    Maxwell, Scott E.
    McCarthy, Michael
    Moore, Don
    Morgan, Stephen L.
    [J]. NATURE HUMAN BEHAVIOUR, 2018, 2 (01): : 6 - 10
  • [9] Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors
    Bhowmik, Arijit
    Khan, Rajni
    Ghosh, Mrinal Kanti
    [J]. BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [10] Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma
    Blobner, Jens
    Dengler, Laura
    Blobner, Sven
    Eberle, Constantin
    Weller, Jonathan
    Teske, Nico
    Karschnia, Philipp
    Ruehlmann, Katharina
    Heinrich, Kathrin
    Ziemann, Frank
    Greif, Philipp A.
    Jeremias, Irmela
    Wuerstlein, Rachel
    Hasselmann, Korbinian
    Dorostkar, Mario
    Harter, Patrick N.
    Quach, Stefanie
    Stoecklein, Veit
    Albert, Nathalie L.
    Niyazi, Maximilian
    Tonn, Joerg-Christian
    Thon, Niklas
    Westphalen, Benedikt Christoph
    von Baumgarten, Louisa
    [J]. NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)